drugset / Trial / NCT01586455
Human Placental-Derived Stem Cell Transplantation
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.
Timeline
- Start
- 2013-04
- Primary completion
- 2020-06
- Completion
- 2022-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Placental Derived Stem Cell | Cell therapy | — | — |
Indications
Diamond-Blackfan anemia
Gaucher disease
Krabbe disease
Niemann-Pick disease
Wolman disease
acute lymphoblastic leukemia
acute myeloid leukemia
adrenoleukodystrophy
fucosidosis
juvenile neuronal ceroid lipofuscinosis
metachromatic leukodystrophy
mucopolysaccharidosis type 1
mucopolysaccharidosis type 6
myelodysplastic syndrome
thrombocytopenia